The long-term efficacy of gene therapy for Leber Hereditary Optic Neuropathy (LHON) has received a significant boost with the publication of five-year data from the RESTORE clinical trial. Published in JAMA Ophthalmology, the study confirms that a single unilateral administration of the gene therapy lenadogene nolparvovec (Lumevoq) results in sustained bilateral improvement in visual acuity for patients with LHON caused by the MT-ND4 gene variant.
Lenadogene nolparvovec is an adeno-associated virus (AAV)–based ocular gene therapy designed to deliver a functional copy of the ND4 gene to the retinal ganglion cells. The RESTORE study serves as the five-year follow-up to the phase 3 RESCUE and REVERSE clinical trials, which initially evaluated the therapy's safety and efficacy up to two years post-administration.
The RESTORE trial included 62 patients from the original studies, with 55 completing the five-year examination. The results demonstrated that patients sustained a clinically meaningful bilateral improvement in best-corrected visual acuity (BCVA). This bilateral effect following a unilateral injection is a unique and highly beneficial characteristic of the therapy, providing significant improvements in the patients' quality of life.
In addition to the sustained visual gains, the therapy maintained a good overall safety profile up to five years after treatment, with no serious ocular adverse events reported. The most common adverse event was intraocular inflammation, which was generally mild and responsive to standard treatments.
These findings provide compelling evidence for the persistent benefit of lenadogene nolparvovec, reinforcing its potential as a long-term, disease-modifying treatment for patients suffering from the most common genetic cause of LHON. The sustained efficacy and safety profile offer renewed hope for individuals facing the devastating vision loss associated with this condition.
Medical Disclaimer: This information is for educational purposes only and does not constitute medical advice. Genetic testing and clinical management should be performed by qualified healthcare professionals.